De Marzio P, Morelli S, Suppa M, Caputo V, Mango L, Guido V, Cardoni F, Gnecchi M, Aguglia F
Istituto di Clinica Medica, Università degli Studi di Roma La Sapienza.
Minerva Cardioangiol. 1991 Jan-Feb;39(1-2):35-9.
Anti-arrythmia efficacy and effects on left ventricular function of flecainide have been evaluated in 9 patients with symptomatic non sustained ventricular tachycardia (NSVT) and left ventricular ejection fraction (LVEF) lower than 30%, respectively detected by Holter monitoring and radionuclide angiocardiography in basal conditions. Seven to eleven days after starting flecainide therapy (100 mg b.i.d.), Holter and radionuclide angiocardiography were repeated. In 56% of patients a ventricular premature beats (VPB) reduction more than 70% was obtained and total VPB suppression was achieved in 33% of patients. Total suppression of NSVT was obtained in 67% of patients; LVEF did not show significant changes. Thus, antiarrhythmic efficacy of flecainide resulted in agreement with the previous reports, whereas no patient developed signs or symptoms of heart failure or pro-arrhythmia.
在9例有症状的非持续性室性心动过速（NSVT）患者中评估了氟卡尼的抗心律失常疗效及其对左心室功能的影响，这些患者的左心室射血分数（LVEF）低于30%，分别通过基础状态下的动态心电图监测和放射性核素心血管造影检测。在开始氟卡尼治疗（100mg，每日两次）7至11天后，重复进行动态心电图和放射性核素心血管造影检查。56%的患者室性早搏（VPB）减少超过70%，33%的患者实现了VPB的完全抑制。67%的患者实现了NSVT的完全抑制；LVEF未显示出显著变化。因此，氟卡尼的抗心律失常疗效与先前的报道一致，且没有患者出现心力衰竭或促心律失常的体征或症状。
